Ito J, Okada M, Abo T, Okamoto Y, Yamashita T, Takahashi K
Gan To Kagaku Ryoho. 1987 Mar;14(3 Pt 1):706-10.
In order to search for methods of controlling cisplatin-induced emesis, a series of experiments were performed with dogs. Cisplatin was administered i.v. to dogs at three-day intervals, and the number of emetic episodes and latency period to the first episode following injection were examined. The dose of cisplatin was 0.3mg/kg at the first injection, and thereafter square root 2-fold higher doses than the preceding ones were injected up to a maximum of 2.4 mg/kg. Emesis was observed from 0.42 g/kg. The number of emetic episodes increased with escalation of the dose up to 0.85 mg/kg, but decreased at higher doses. On the other hand, the latency period shortened with increase of the dose up to the highest one. From these results, the latency period is concluded to be a reliable parameter for evaluating the emetic activity of cisplatin and the efficacy of anti-emetics. The anti-emetic effect of vagotomy, ethyl amino-benzoate or metoclopramide was then examined. When 1 mg/kg of cisplatin was administered i.v., mean values of latency period and the number of episodes in dogs of a control group were 200 minutes and 20 times, respectively. In vagotomized dogs, no emesis was observed. When ethyl amino-benzoate was administered p.o. at doses of 12, 24 and 48 mg/kg 30 minutes before and 90 minutes after cisplatin injection, the number of episodes decreased to between 8 and 4.3 times, but the latency period was not prolonged. When s.c. injections of 1 mg/kg metoclopramide were combined with cisplatin in a similar manner to ethyl amino-benzoate, the latency period was prolonged up to 343 minutes, and the number of episodes decreased to 2.7 times. These results suggest that the peripheral autonomic nervous system is involved in the mechanism of emesis induction by cisplatin. Finally, the anti-emetic effect of metoclopramide was examined using the following administration schedules of cisplatin: a single i.v. injection of 3.75 mg/kg and daily i.v. injections of 1.25 mg/kg for three days. Metoclopramide showed a superior anti-emetic effect in the latter schedule, when the dose of 2 mg/kg was given i.v. 30 minutes before and 90 and 210 minutes after the cisplatin injection.
为了寻找控制顺铂所致呕吐的方法,用犬进行了一系列实验。顺铂以静脉注射方式每隔三天给予犬一次,观察呕吐发作次数及注射后首次发作的潜伏期。首次注射顺铂的剂量为0.3mg/kg,此后每次注射剂量为前一次的√2倍,最大剂量为2.4mg/kg。从0.42g/kg开始观察到呕吐。呕吐发作次数随剂量增加至0.85mg/kg而增多,但在更高剂量时减少。另一方面,潜伏期随剂量增加直至最高剂量而缩短。从这些结果得出结论,潜伏期是评估顺铂致吐活性及止吐药疗效的可靠参数。接着研究了迷走神经切断术、氨基苯甲酸乙酯或甲氧氯普胺的止吐作用。静脉注射1mg/kg顺铂时,对照组犬的潜伏期平均值和发作次数分别为200分钟和20次。迷走神经切断的犬未观察到呕吐。在顺铂注射前30分钟及注射后90分钟口服给予氨基苯甲酸乙酯,剂量分别为12、24和48mg/kg,发作次数减少至8至4.3次,但潜伏期未延长。当以与氨基苯甲酸乙酯类似的方式将1mg/kg甲氧氯普胺皮下注射与顺铂联合应用时,潜伏期延长至343分钟,发作次数减少至2.7次。这些结果提示,外周自主神经系统参与了顺铂致吐机制。最后,采用以下顺铂给药方案研究甲氧氯普胺的止吐作用:单次静脉注射3.75mg/kg和顺铂连续三天每天静脉注射1.25mg/kg。当在顺铂注射前30分钟、注射后90分钟和210分钟静脉注射2mg/kg甲氧氯普胺时,在后一种给药方案中其止吐效果更佳。